Struggling DNA testing firm 23andMe to be bought for $256m

Struggling DNA testing firm 23andMe to be bought for $256m 7 minutes ago Share Save Lily Jamali • @lilyjamali North America Technology Correspondent Reporting from San Francisco, CA Share Save Reuters The DNA testing firm 23andMe says it has entered into an agreement to be acquired by Regeneron Pharmaceuticals for $256m (£192m). It comes two months after the company filed for bankruptcy protection in the US. 23andMe said Regeneron had committed to comply with its privacy policies as part of the deal, and that Regeneron has security controls in place to protect user data. Last month, the firm agreed to have an ombudsman oversee the protection of user data in response to demands by several state attorneys general in the US. The officials expressed concern over the potential for unscrupulous buyers to wield the data against consumers. Regeneron will acquire nearly all of 23andMe's assets, the company said in a statement. Its subsidiary Lemonaid Health will be wound down under the agre ... Read full article.